MacroGenics rises in multiple cancers
MacroGenics MGA271 (enoblituzumab) had its PTSR rise in multiple cancer indications on the back of a Phase I basket trial completion. Enoblituzumabs PTSR jumped by 11 points to 76% in transitional cell cancer (TCC), a common type of bladder cancer. The assets PTSR also increased by 12 points in urethral and ureter cancers to 78%, as well as 12 points in squamous non-small cell lung cancer (NSCLC) to 77%.
The 145-patient Phase Is (NCT02475213) status update went live on ClinicalTrials.gov on 28 September. The assets PTSR was apprised the day after. The update also noted that the study was expanded from having two to four treatment arms and completed on 18 August. The two original arms investigated enoblituzumab with either Mercks Keytruda (pembrolizumab) or MacroGenics own anti-PD1 MGA012 (retifanlimab). The two new arms investigated higher doses of enoblituzumab with Keytruda.
Enoblituzumab is a monoclonal antibody that targets B7-H3, a protein that may play a role in regulating immune response in various cancer types. Despite the PTSR changes, enoblituzumabs LoA remained static at 1% in urethral and ureter cancers, though it increased by two points to 8% in squamous NSCLC and 1 point to 7% in TCC. The Phase I trial also recruited melanoma and head and neck cancer patients.